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Abstract: Accumulating evidence supports a role for viruses in the pathogenesis of type 1 
diabetes  mellitus  (T1DM).  Activation  of  dsRNA-sensing  pathways  by  viral  dsRNA 
induces the production of inflammatory cytokines and chemokines that trigger beta cell 
apoptosis,  insulitis,  and  autoimmune-mediated  beta  cell  destruction.  This  study  was 
designed to evaluate and describe potential protective effects of phenylmethimazole (C10), 
a small molecule which blocks dsRNA-mediated signaling, on preventing dsRNA activation of 
beta cell apoptosis and the inflammatory pathways important in the pathogenesis of T1DM. 
We first investigated the biological effects of C10, on dsRNA-treated pancreatic beta cells 
in culture. Cell viability assays, quantitative real-time PCR, and ELISAs were utilized to 
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evaluate  the  effects  of  C10  on  dsRNA-induced  beta  cell  cytotoxicity  and 
cytokine/chemokine production in murine pancreatic beta cells in culture. We found that 
C10  significantly  impairs  dsRNA-induced  beta  cell  cytotoxicity  and  up-regulation  of 
cytokines and chemokines involved in the pathogenesis of T1DM, which prompted us to 
evaluate  C10  effects  on  viral  acceleration  of  T1DM  in  NOD  mice.  C10  significantly 
inhibited viral acceleration of T1DM in NOD mice. These findings demonstrate that C10 
(1) possesses novel beta cell protective activity which may have potential clinical relevance 
in T1DM and (2) may be a useful tool in achieving a better understanding of the role that 
dsRNA-mediated responses play in the pathogenesis of T1DM. 
Keywords: type 1diabetes; dsRNA; beta cell death; phenylmethimazole (C10) 
 
1. Introduction 
Accumulating evidence supports a role for viruses in the pathogenesis of type 1 diabetes mellitus 
(T1DM)  [1–20].  Viral  infection  of  beta  cells  can  initiate  disease  by  direct  cell  damage,  beta  cell 
toxicity from the acute innate antiviral response, or release/induction of endogenous beta cell self-antigens 
triggering autoimmune destruction [11,13,14,21,22]. Double-stranded RNA (dsRNA) is a molecular 
intermediate  formed  during  the  replication  cycle  of  many  viruses.  Activation  of  dsRNA-sensing 
pathways  such  as  TLR3  and  RIG1  by  dsRNA  leads  to  beta  cell  apoptosis  and  expression  of  
pro-inflammatory  genes  known  to  be  important  in  the  development  of  T1DM  [23,24].  
Polyinosinic-polycytidylic acid (pIC) is a synthetic dsRNA that mimics host responses triggered by 
viral  dsRNA,  including  direct  viral  toxicity  and  antiviral  responses  that  can  trigger  autoimmune 
mechanisms. For example, pIC induces apoptosis of beta cells and impairs beta cell function [24]. 
High doses of pIC precipitated diabetes in both diabetes-prone BB (DP-BB) and diabetes-resistant 
(DR-BB) rats [25,26] and accelerated the onset of T1DM in non-obese
 diabetic (NOD) mice [27]. In 
addition, pIC has been shown to induce insulitis and accelerate the progression to T1DM in RIP B7.1 
mice [28], and induce insulitis, but not T1DM, in BALB/c mice [29]. Type 1 interferons (specifically, 
IFN and IFN), which are strongly induced by pIC, have been associated with the pathogenesis of 
T1DM [24,30–33], and their therapeutic use in diseases, such as chronic active hepatitis, has triggered 
autoimmune diseases including T1DM [34]. These type 1 interferons have been shown to accelerate 
the onset of diabetes in NOD mice, induce insulitis in diabetes resistant strains [35], and are present in 
the beta cells of recent-onset T1DM patients [31,36]. pIC also induces other inflammatory mediators 
that  exacerbate  the  autoimmune  process,  including  CXCL10  and  major  histocompatibility  (MHC) 
Class I and II molecules [37,38].  
We  have  previously  shown  that  phenylmethimazole  (C10),  a  small  molecule  derivative  of 
methimazole,  effectively  blocks  dsRNA  induction  of  co-stimulatory  and  adhesion  molecules, 
chemokines, pro-inflammatory cytokines and their receptors, and MHC gene expression in thyrocytes, 
pancreatic cancer cells, and melanoma cells [37–39]. More recently, we demonstrated that C10 blocks 
dsRNA-induced IRF3 homodimer formation in pancreatic ductal epithelioid carcinoma cells [40], an 
important step in the TLR3 and RIG1 signaling pathways [23,41]. This suggests that C10 may have Molecules 2013, 18  3843 
 
 
biological  activities  that  protect  pancreatic  beta  cells  from  dsRNA-induced  beta  cell  death  and 
upregulation of many cytokines and chemokines involved in the pathogenesis of T1DM. Thus, these 
studies were designed to evaluate and describe potential beneficial biological effects C10 may have on 
preventing  dsRNA  activation  of  beta  cell  apoptosis  and  inflammatory  pathways  important  in  the 
development of T1DM as well as to evaluate efficacy of C10 to block viral acceleration of T1DM in vivo.  
2. Results and Discussion 
2.1. C10 Protects Pancreatic Beta Cells from dsRNA-Induced Cytotoxicity 
In order to study the effects of C10 on dsRNA-induced beta cell cytotoxicity, we utilized two 
mouse pancreatic beta cell lines, TC-6 and NIT-1, in culture. NIT-1 cells are derived from the NOD 
mouse [42], which is genetically prone to spontaneously develop autoimmune-mediated T1DM, whereas 
TC-6 cells are derived from transgenic mice that do not spontaneously develop autoimmune-mediated 
T1DM [43,44]. Thus, the inflammatory response to dsRNA in NIT-1 cells is expected to be most 
representative of the inflammatory response to dsRNA that occurs in vivo in the NOD mouse model, 
which triggers an autoimmune-mediated (Pattern A) form of T1DM [20,45,46]. However, the effects 
of  dsRNA  on  TC-6  beta  cell  viability  is  expected  to  be  most  representative  of  the  direct  viral 
cytotoxicity seen in the Pattern B form of T1DM [20,45,46]. 
Transfection of TC-6 cells with a low concentration of pIC (1 μg/mL) steadily decreased cellular 
viability over a 48-hour period (Figure 1A) while higher concentrations of pIC (10 μg/mL) did not 
further increase this cytotoxic effect (Figure 1B). Treatment with C10 significantly diminished the 
cytotoxic effects of pIC transfection with either low (Figure 1A) or high concentrations (Figure 1B), 
although it was not as protective at the higher concentration of pIC. The solvent used for dissolving 
C10 (a solution containing 0.25% DMSO) provided no protection of TC-6 cells transfected with either 
concentration of pIC except at the 24-hour  time  point where it provided only minimal protection 
(Figure 1A,B). 
Similar results were obtained in NIT-1 cells. Transfection of NIT-1 cells with pIC (1 μg/mL) also 
reduced cell viability in a dose-dependent manner (Figure 1C,D) with higher concentrations (10 μg/mL) 
inducing greater cytotoxicity (Figure 1D). NIT-1 cells treated with C10 following pIC transfection 
(Figure 1C,D) were protected from the cytotoxic effects of pIC at both concentrations (Figure 1C,D) 
similar to that seen with the TC-6 cells, while the solvent had no effect on NIT-1 cell viability. 
These  data  are  consistent  with  previous  studies  demonstrating  the  cytotoxic  effect  of  pIC  in 
pancreatic beta cells [24] and show for the first time that C10 suppresses the acute induction of beta 
cell  toxicity  in  response  to  dsRNA  in  both  transfected  beta  cell  lines.  The  cytotoxic  effect  of 
transfection with pIC on the NIT-1 cell line was concentration-dependent, while the TC-6 cell line was 
much more sensitive to the pIC treatment because the low dose rapidly induced cytotoxicity. This 
result contrasts with the observation of Robbins et al. who reported that higher concentrations of pIC 
did not increase cytotoxicity in NIT-1 cells [47]. One explanation for this discrepancy may be that the 
longer exposure of cells (48 h) to pIC-liposome complexes in our studies results in the activation of 
additional factors involved in programmed cell-death pathways. Molecules 2013, 18  3844 
 
 
In sum, C10 suppresses the cytotoxic effects of dsRNA on both transfected beta cell lines, suggesting 
that C10 may prevent viral induction of beta cell death seen in both Pattern A and B forms of T1DM. 
Figure 1. C10 prevents pIC-induced cytotoxicity in pancreatic beta cells in culture. TC-6 
and NIT-1 cells were transfected with 1 mg/mL (A & C) and 10 mg/mL (B & D) of pIC. 
TC-6  and  NIT-1  cells  were  either  mock  transfected  (—  □  —),  transfected  with  pIC  
(
… ○ 
…), or transfected with pIC and treated with either DMSO (solvent)(– – Δ – –) or 0.5 mM 
C10 (– ·  ■ – · ) for the indicated times. At 6, 12, 24, and 48 h post-transfection, the viability 
of cells was measured using the Cell Titer-Glo Luminescent Cell Viability Assay. 
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2.2. C10 Blocks dsRNA-Induced Upregulation of TLR3 Expression and Signaling Products in 
Pancreatic Beta Cells 
It is hypothesized that the pancreatic beta cell itself is an important source of the pro-inflammatory 
cytokines that mediate beta cell apoptosis, as well as expression/release of intracellular auto-antigens 
propagating  the  autoimmune-mediated  beta  cell  destruction.  Furthermore,  dsRNA  activation  of 
dsRNA-sensing pathways, such as TLR3, triggers the production of these pro-inflammatory cytokines 
and chemokines in beta cells [23]. Since we have previously shown that C10 is a potent inhibitor  
of  dsRNA-induction  of  the  same  pro-inflammatory  cytokines  and  chemokines  involved  in  the 
development of T1DM (CXCL10, IFN, TNF, TLR3, and MHC Class I) in other non-immune cell 
types [37–40], we hypothesized that C10 may also be an important and potent inhibitor of dsRNA-induced 
production of these cytokines and chemokines in pancreatic beta cells. To test this hypothesis, we 
transfected NIT-1 cells with pIC in the presence or absence of C10 and evaluated CXCL10, IFN, 
TNF, TLR3, and MHC Class I gene expression. Comparative multiplex real-time PCR was used to 
characterize the effects of pIC transfection on the expression of TLR3 and TLR3 signaling products 
and to determine the effect of C10 or its vehicle (DMSO) in NIT-1 cells in culture. While after 4 h 
there was no induction of TLR3 gene expression by pIC transfection (Figure 2A), however, by 6 h 
post-transfection, induction of TLR3 gene expression was evident (Figure 2F). Additionally, while 
there was no stimulation of TLR3 by 4 h post-pIC treatment, none-the-less, C10 suppressed TLR3 
below  basal  expression  following  treatment  at  this  time  point  (Figure  2A),  and  prevented  pIC 
upregulation of TLR3 gene expression at 6 h post pIC treatment (Figure 2F). pIC transfection also 
significantly increased CXCL10, IFN, and TNF gene expression while C10 significantly blocked 
pIC stimulation of CXCL10, IFN, and TNF expression (Figure 2B–D). Similar to its effect on 
TLR3 expression, C10 also significantly reduced basal MHC Class I gene expression (Figure 2E). 
Although pIC did not up-regulate MHC Class I expression above basal levels, C10 did significantly 
reduce  its  expression  below  basal  levels,  suggesting  that  C10  may  be  blocking  basally-activated 
signaling pathways that control its expression. C10 inhibition of pIC-induced TLR3 expression and 
downstream signaling molecules in NIT-1 cells was additionally confirmed by quantitative real-time 
PCR arrays and similar findings were also obtained in TC-6 cells (Tables 1–3). 
In  agreement  with  our  gene  expression  studies  above,  we  observed  a  significant  increase  in 
CXCL10 protein levels following pIC transfection and significant inhibition of pIC-induced CXCL10 
protein levels with C10 treatment (Figure 3). IFN and CXCL10 are thought to be key players in the 
pathogenesis of T1DM. As previously mentioned, type 1 interferons (IFN and IFN) have been 
associated with the pathogenesis of type 1 diabetes [24,30–36,48], and their therapeutic use in diseases 
such as chronic active hepatitis has triggered autoimmune diseases including type 1 diabetes [34]. 
These type 1 interferons accelerate the onset of diabetes in NOD mice [35], induce insulitis in diabetes 
resistant  strains  [35],  and  are  present  in  the  beta  cells  of  recent-onset  diabetic  patients  [31,36]. 
CXCL10 expression in NOD mice is responsible for the targeted migration of autoreactive T-cells into 
the  pancreatic  islets  [49].  Furthermore,  it  has  been  shown  that  notably  high  levels  of  CXCL10, 
followed by CCL2 and CCL5 [50], are constitutively expressed from pancreatic islets, suggesting that 
beta cell production of these chemokines is important in the development of T1DM.  
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Figure 2. C10 suppresses pIC-induced expression of TLR3 and of other genes involved in the 
inflammatory response in NIT-1 cells. Quantitative Real Time PCR was used to characterize 
the expression of TLR3 and cytokines and chemokines involved in mediating insulits and type 
1 diabetes. Total RNA was isolated from NIT-1 cells transfected with 1 μg/mL of pIC using 
Lipofectamine 2000 (LF2000) plus DMSO (solvent) or 0.5 mM C10 for 4 h (A–E), or 6 h 
(F) and gene expression was evaluated using the murine TLR3, CXCL10, IFN, TNF, 
and  MHC  Class  I  Gene  Expression  Assays  (Applied  Biosystems,  Carlsbad,  CA).  Fold 
changes in gene expression were calculated using the ΔΔCt method. Statistical analyses 
were performed using one-way ANOVAs followed by Bonferroni and Tukey-Kramer post-hoc 
analyses.  (A)  *  Indicates  a  significant  reduction  in  TLR3  gene  expression  by  C10,  
p  <  0.00001;  (B–D)  #  Indicates  a  significant  induction  of  gene  expression  by  pIC,  
p < 0.00001, and * indicates a significant reduction in pIC-stimulated gene expression by 
C10, p < 0.00001; (E) * indicates a significant reduction in basal MHC Class I expression, 
p  <  0.001;  and  in  (F)  # Indicates  a  significant induction of TLR3 expression by pIC,  
p < 0.05, and * indicates a significant reduction in pIC-stimulated TLR3 expression by 
C10, p < 0.05.  
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Table 1. Relative fold changes induced by pIC and inhibition by C10 on TLR signaling array. 
Functional Gene 
Groupings/Gene Name    TC-6 cells  NIT-1 Cells 
Pattern Recognition 
Receptors    pIC  pIC + 
DMSO 
pIC +  
C10  pIC  pIC + 
DMSO 
pIC + 
C10 
Toll-Like Receptor 1    5.78  <5  <5  <5  <5  <5 
Toll-Like Receptor 2    8.20  <5  <5  26.17  11.59  <5 
Toll-Like Receptor 3    66.7  23.2  <5  176.0  64.2  <5 
Toll-Like Receptor 4    5.78  <5  <5  <5  <5  <5 
Toll-Like Receptor 6    <5  <5  <5  22.24  <5  <5 
Toll-Like Receptor 7    5.74  <5  <5  <5  <5  <5 
Toll-Like Receptor 8    5.74  <5  <5  <5  <5  <5 
Table 2. Relative fold changes induced by pIC and inhibition by C10 on expression of 
genes in a TLR signaling array. 
Functional Gene Groupings/Gene Name  TC-6 cells  NIT-1 Cells 
  pIC 
pIC + 
DMSO 
pIC + 
C10  pIC 
pIC + 
DMSO 
pIC + 
C10 
TLR adaptor proteins             
Heat shock 70kDa protein 1A (Hspa1a)  <5  <5  <5  20.32  <5  8.30 
TICAM2  <5  <5  <5  9.58  6.57  <5 
Transcription factors             
c-Fos  <5  <5  <5  5.45  <5  <5 
c-Jun  <5  <5  <5  14.37  <5  <5 
CCAAT/enhancer binding protein β (Cebpb)  <5  <5  <5  9.22  <5  <5 
NF-κB pathway             
CCL2  21.50  22.25  <5  172.45  30.70  <5 
CD80  6.03  6.69  <5  40.22  20.97  <5 
CD86  <5  <5  <5  68.12  35.38  <5 
Granulocyte macrophage colony-stimulating 
factor (Csf2) 
<5  <5  <5  5.92  <5  <5 
Granulocyte colony-stimulating factor (Csf3)  <5  <5  <5  6.80  <5  <5 
IKKα (Chuk)  <5  <5  <5  5.37  <5  <5 
IL-1α  <5  <5  <5  7.31  <5  <5 
IL-2  5.78  <5  <5  <5  <5  <5 
IL-6  8.91  8.98  <5  580.04  143.01  <5 
IL-6 Receptor α (IL-6ra)  <5  <5  <5  25.46  <5  <5 
IL-10  <5  <5  <5  57.68  22.24  <5 
IL-12A  6.62  <5  <5  10.78  22.09  <5 
NF-κB2   8.52  <5  <5  22.86  16.56  <5 
IκBα (Nfkbia)  <5  <5  <5  13.50  <5  <5 
IκBβ (Nfkbib)  <5  <5  <5  14.47  <5  <5 
Prostaglandin-endoperoxide synthase 2 
(Ptgs2) 
<5  <5  <5  48.34  17.69  <5 
TNF-α  5.78  <5  <5  26.72  6.70  <5 
TNF-β (Lta)  NS  <5  <5  45.57  38.59  <5 
Tumor necrosis factor, alpha-induced protein 
3 (Tnfaip3) 
7.87  <5  <5  <5  <5  <5 
IRF pathway             
IP-10 (CXCL10)  189.49  74.85  <5  543.07  141.53  <5 
IFN-β1  135.86  72.81  <5  2778.33  196.04  <5 
IRF-1  6.85  6.32  <5  12.04  11.24  <5 
NS = > 5-fold, but not statistically significant p > 0.05. Molecules 2013, 18  3848 
 
 
Table 3. Relative fold changes induced by pIC and inhibition by C10 on expression of 
inflammatory cytokine gene array. 
Functional Gene Groupings/Gene Name  TC-6 Cells  NIT-1 Cells 
    pIC 
pIC + 
DMSO 
pIC + 
C10 
pIC 
pIC + 
DMSO 
pIC + 
C10 
Chemokines               
CCL2    13.60  6.96  <5  160.12  25.05  <5 
CCL4    39.15  5.94  <5  25.33  25.58  <5 
CCL5    320.9  112.21  <5  1245.92  384.54  <5 
CCL7    18.2  14.42  <5  107.49  91.90  <5 
CCL9    <5  <5  <5  6.86  <5  <5 
CCL12    8.76  <5  <5  19.95  8.80  <5 
CCL19    <5  <5  <5  26.32  32.38  64.40 
CCL20    183.67  54.19  <5  76.27  43.17  <5 
CCL25    23.36  21.33  <5  <5  <5  <5 
CXCL1    7.57  <5  <5  <5  <5  <5 
CXCL5    5.86  <5  <5  <5  10.14  <5 
CXCL9    58.32  17.94  <5  344.41  275.71  <5 
CXCL10    150.23  133.9  <5  522.03  170.31  <5 
CXCL11    <5  <5  <5  74.70  67.51  <5 
Chemokine receptors               
CCR10    179.27  57.48  <5  <5  <5  <5 
Cytokines               
IL-1F6    <5  <5  <5  38.94  15.97  <5 
IL-4    41.53  11.84  <5  <5  <5  <5 
IL-10    <5  <5  <5  28.11  10.87  <5 
IL-11    33.61  10.67  <5  19.00  8.65  <5 
IL-15    139.68  43.26  <5  36.45  35.19  <5 
Osteopontin (Spp1)    18.33  NS  <5  <5  <5  <5 
TGF-β1    62.51  20.32  <5  <5  <5  <5 
TNF-α    <5  <5  <5  21.38  5.76  <5 
TNF-β (Lta)    <5  <5  <5  38.27  34.82  <5 
Lymphotoxin-β (Ltb)    299.41  13.83  <5  <5  <5  <5 
Cytokine receptors               
Glycoprotein 130 (IL-6st)    324.26  110.66  <5  <5  <5  <5 
IL-1R2    21.27  5.82  <5  <5  <5  <5 
IL-5Rα    11.88  <5  <5  <5  <5  <5 
Tumor necrosis factor receptor superfamily 
1B (Tnfrsf1b) 
−23.65  −62.47  <5  <5  <5  <5 
Integrin β2 (Itgb)    <5  <5  <5  10.54  <5  <5 
Other inflammatory genes               
Caspase 1 (Casp1)    17.52  6.06  <5  15.98  7.02  −6.15 
NS = > 5-fold, but not statistically significant p > 0.05. 
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Figure 3. C10 blocks pIC-stimulated CXCL10 protein levels. CXCL10 protein levels were 
measured in the cell culture supernatants from NIT-1 cells transfected with 1 μg/mL of pIC 
plus DMSO (solvent) or 0.5 mM C10 for 4 h using the mouse CXCL10/IP-10 Quantikine 
ELISA  kit  from  R  &  D  Systems.  Statistical  analysis  was  performed  using  a  one-way 
ANOVA  followed  by  Bonferroni  and  Tukey-Kramer  post-hoc  analysis.  #  Indicates  a 
significant  induction  of  CXCL10  protein  levels  by  pIC,  p  <  0.05,  and  *  indicates  a 
significant reduction in pIC-stimulated CXCL10 protein levels by C10, p < 0.05. 
 
Elevated serum levels of CXCL10 have also been observed in patients with T1DM as well as in 
islet-cell autoantibody positive individuals who are at risk for developing T1DM [51,52]. Pathogenic 
Th1  cells  predominately  express  CXCR3,  the  receptor  for  CXCL10,  suggesting  that  CXCL10 
accelerates  the  autoimmune  process  by  promoting  the  migration  of  autoreactive  Th1  cells  to  the 
pancreas [53]. In our current studies pIC strongly induced the expression of IFN and CXCL10 in 
NIT-1 cells by over 120 fold, while C10 completely suppressed pIC-induced expression of both genes 
(IFN and CXCL10). Together, the fact that these genes are critical to the development of type 1 
diabetes and that C10 dramatically reduces pIC induction of these genes in beta cells further supports 
the idea that C10 may be useful for the prevention of viral-induced type 1 diabetes (both pattern A and 
pattern  B).  Presently,  the  major  barrier  to  such  use  is  the  lack  of  sensitivity  and  specificity  in 
identifying those individuals at risk [54]. 
2.3. C10 Attenuates Coxsackievirus B4 (CVB4) Acceleration of T1DM in Non-Obese Diabetic (NOD) Mice 
Since C10 significantly blocked dsRNA induction of beta cell death and upregulation of cytokines 
and chemokines important in the development of T1DM, we investigated the possibility that C10 may 
block viral induction of T1DM in vivo. To test the hypothesis that C10 may be useful to block viral 
induction of type 1 diabetes, we utilized the coxsackievirus B4 (CVB4)-induced NOD mouse model of 
type 1 diabetes [55]. Acceleration of T1DM in NOD mice by CVB4 can only be achieved once a 
critical  mass  of  autoreactive  T  cells  is  present  in  pancreatic  islets  [55].  If  this  critical  mass  of 
autoreactive T cells is not present in pancreatic islets prior to infection, then CVB4 infection provides Molecules 2013, 18  3850 
 
 
long-term protection from disease expression [55]. Serreze et al. previously established that once NOD 
mice have accumulated a naturally occurring critical mass of pancreatic islet autoreactive T cells, 
which  occurs in  most NOD  mice  by  8 weeks of age,  a significant  acceleration of T1DM  can  be 
observed following inoculation with CVB4 [55]. Thus, we infected 8 week old NOD mice with CVB4 
as previously described [55] and observed the incidence of diabetes over a 16 week period. For this 
experiment,  groups  of  mice  (infected  or  un-infected  controls)  were  treated  with  a  sham  injection 
(intraperitoneal needle stick only) as a stress control, or were treated once daily with intraperitoneal 
injections of DMSO (solvent) or C10 (1 mg/kg). Consistent with previous observations [55], CVB4 
infection of 8 week old NOD mice resulted in a rapid acceleration of diabetes, with 50% of mice 
becoming diabetic by 2 weeks post CVB4 infection (10 weeks of age) (Figure 4A, shaded region). 
Similar results were observed in DMSO-treated NOD mice infected with CVB4, where we observed 
that 38% of mice were diabetic by 2 weeks post CVB4 infection (Figure 4A, shaded region). In contrast, 
only 7% of C10-treated NOD mice infected with CVB4 were diabetic by that time (Figure 4A, shaded 
region), indicating that C10 effectively reduced CVB4 acceleration of T1DM in NOD mice. NOD 
mice not treated with virus but treated daily with sham, DMSO, or C10 injections were also included 
in this study, however no animals in any of these groups were diabetic by 10 weeks of age (Figure 4A, 
dashed  lines).  After  the  initial  CVB4-induced  spike  in  diabetes  within  the  first  2  weeks  (viral 
acceleration phase), we observed a plateau in diabetes development in all virus infected groups which 
preceded a subsequent gradual increase in diabetes development (Figure 4A). This plateau effect is in 
agreement with previous observations [55], and reflects what we believe to be the period of prolonged 
protection from disease expression mentioned above which is conferred by CVB4 in mice that did not 
have a ―critical threshold‖ of insulitis present at the time of infection [55]. The gradual increase in 
incidence of diabetes following this plateau is likely due to the genetic predisposition of NOD mice to 
spontaneously develop T1DM at this age [55]. The pattern of diabetes development in non-virus-
infected  NOD  mice  indicates  the  spontaneous  development  of  T1DM  that  is  observed  in  this 
genetically predisposed strain of mice. It is noteworthy that we observed no effect of C10 on the 
spontaneous (genetically determined component) development of T1DM in the NOD mouse, which 
supports our hypothesis that C10’s protective effects are specific to molecular pathways involved in 
the environmental induction/acceleration of disease expression. 
It is also noteworthy to mention that we observed no apparent toxic effects in the mice treated with 
C10. NOD mice treated with C10 for an extended period of time (16 weeks) show no signs of toxicity 
related to the C10 treatment [i.e., C10-treated animals are comparable in weight to control-treated 
animals (Figure 4B) and showed no additional signs of distress (i.e., cachexia, poor grooming, absence 
of normal dietary patterns)] throughout the duration of the experiment. In addition, we observed no 
beta cell toxicity of C10 in any of our cell culture experiments described herein, nor have we seen 
toxicity of C10 in any of our previously published in vitro or in vivo studies [37–40,56,57]. Together, 
this suggests toxicity associated with C10 is minimal and that C10 is likely to be as well tolerated or 
possibly better tolerated than its parent compound methimazole. 
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Figure 4. C10 attenuates CVB4 acceleration of type 1 diabetes in NOD mice without toxicity. 
Eight week old female mice were either infected intraperitoneally with 500,000 pfu of 
CVB4 or mock infected and/or treated with 1 mg/kg C10, DMSO (solvent control), or 
sham injection (stress control) as indicated. Incidence of diabetes and weights of mice in 
each  group  were  recorded  weekly.  (A)  Effect  of  indicated  treatment  on  incidence  of 
diabetes  in  NOD  mice  infected  with  CVB4  (solid  lines)  or  uninfected  (dashed  lines).  
(B) Effect of indicated treatment on weight of NOD mice. 
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3. Experimental  
3.1. Reagents  
C10 was provided by the Interthyr
 Corporation (Marietta, OH, USA). A 200 mM stock solution of 
C10 was dissolved in dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO, USA), which was further 
diluted  to  0.5  mM  for  in  vitro  experiments  in  culture  medium.  pIC  was  purchased  from  Sigma  
(St.  Louis,  MO,  USA).  Edward’s  CVB4  was  kindly  provided  by  Dr.  Roger  Loria,  Virginia 
Commonwealth University. 
3.2. Cell Culture and Transfections  
NIT-1 and TC-6 beta cell lines were purchased from American Type Culture Collection (ATCC) 
(Manassas, VA, USA). NIT-1 cells were cultured in Ham's F12K medium (ATCC) supplemented with 
10% heat-inactivated dialyzed fetal bovine growth serum (FBS, Gibco, Carlsbad, CA, USA). TC-6 
cells  were  cultured  in  Dulbecco’s  Modified  Eagle  Medium  (Hyclone,  Red  Bank,  NJ,  USA) 
supplemented with 15% FBS (Hyclone). Cells were incubated at 37 ° C in a humidified atmosphere of 
5% CO2. Cells were transfected with pIC using Lipofectamine 2000 (LF2000) (Invitrogen, Carlsbad, 
CA, USA). Serum-free media with liposome complexes was replaced at 24 h post-transfection with 
appropriate cell culture media for experiments lasting longer than 24 h. 
3.3. Cellular Viability Assays  
Cells were seeded in triplicate at a density of 2.5 ×  10
4 cells per well. The number of viable cells 
was quantified with the Cell Titer-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA). 
Luminescence  was  measured  with  the  Lumat  LB  9507  luminometer  (Berthold  Technologies,  Oak 
Ridge, TN, USA). A standard curve was generated to correlate cell numbers with luminescence activity. 
3.4. Quantitative Real Time PCR 
Total RNA was isolated (RNeasy Kit, Qiagen, Valencia, CA, USA), treated with DNase (RNase-Free 
DNAse Kit, Qiagen), and quantified with the RNA 6000 Nano Chip (Agilent Technologies, Santa 
Clara, CA, USA) and the 2100 Bioanalyzer (Agilent Technologies). cDNA was synthesized using  
the  High  Capacity  cDNA  Reverse  Transcription  Kit  (Applied  Biosystems,  Carlsbad,  CA,  USA).  
Pre-amplification of cDNA was done using the TaqMan PreAmp Master Mix Kit (Applied Biosystems, 
Carlsbad, CA, USA). Real-time PCR was performed using murine CXCL10, IFN, TNF, TLR3, and 
MHC Class I Gene Expression Assays (Applied Biosystems). Non-preamplified cDNA was used for 
CXCL10 real-time PCR, whereas pre-amplified cDNA was used to amplify IFN, TNF, TLR3, and 
MHC Class I by real-time PCR. Changes in gene expression were calculated using the ΔΔCt method. 
3.5. Quantitative Real Time PCR Arrays 
TC-6 and NIT-1 cells were transfected with pIC in the presence or absence of C10 or DMSO 
(solvent) for 24 h. Total RNA was isolated (RNeasy MiniElute Cleanup Kit, Qiagen) and quantified 
with  the  RNA  6000  Nano  Chip  (Agilent  Technologies)  and  the  2100  Bioanalyzer  (Agilent Molecules 2013, 18  3853 
 
 
Technologies). cDNA was synthesized using the RT²  First Strand Kit (SABiosciences, Frederick, MD, 
USA). Real-time PCR was performed with the Mouse Toll-Like Receptor Signaling Pathway PCR 
Array  (SABiosciences)  and  the  Mouse  Inflammatory  Cytokines  and  Receptors  PCR  Array 
(SABiosciences) using the Mx3000P QPCR system (Stratagene, La Jolla, CA, USA). Fold changes in 
gene expression were calculated using the ΔΔCt method. Statistical analysis was performed using the 
two-tailed paired Student’s t-test, and a p-value of less than 0.05 was considered significant. 
3.6. CXCL10 ELISA 
CXCL10  protein  levels  were  measured  in  the  cell  culture  supernatants  using  the  mouse 
CXCL10/IP-10 Quantikine ELISA kit according to the manufacturer’s instructions (R&D Systems, 
Minneapolis, MN, USA). 
3.7. NOD Mouse Experiment 
Mice were housed in a sterile/pathogen free facility. Seven week old wild-type NOD female mice 
were obtained from Jackson Labs (Bar Harbor, ME, USA) and allowed to acclimate for 1 week prior to 
initiation of studies. Eight week old NOD mice were infected by intraperitoneal (i/p) injection with  
5 ×  10
5 plaque forming units of CVB4 [58]. Indicated animals received daily i/p sham injections and/or 
daily injections of DMSO (control solvent) or 1 mg/kg C10 following CVB4 infection. Non-infected 
control mice received similar sham, DMSO, or C10 treatments. Weight and blood glucose were measured 
weekly. Diabetes was defined as blood glucose values exceeding 240 mg/dL on consecutive days  
(at least 24 h apart) and confirmed by urinary glucose excretion (Diastix, Bayer, Pittsburgh, PA, USA). 
4. Conclusions  
The results described herein indicate that C10 significantly protects beta cells from dsRNA-induced 
cytotoxicity and up-regulation of cytokines involved in beta cell destruction in beta cells in culture. 
Moreover, we report the novel finding that C10 protects NOD mice from CVB4-induced acceleration 
of  T1DM.  Together,  these  results  demonstrate  that  C10:  (1)  possesses  novel  beta  cell  protective 
activity from dsRNA induction of apoptosis and inflammation; (2) protects genetically predisposed 
NOD  mice  from  CVB4-induced  acceleration  of  T1DM,  suggesting  that  C10  may  have  potential 
clinical relevance for T1DM; and (3) may be a useful tool to glean a greater understanding of the role 
that dsRNA-mediated responses play in the pathogenesis of T1DM. 
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